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Objective: Left ventricular assist devices are increasingly used as a bridge to trans-
plantation. It remains unclear whether the use of pretransplant left ventricular assist
devices adversely affects short-term survival after cardiac transplantation.
Methods: A retrospective review of 317 consecutive patients undergoing cardiac
transplantation at an academic center between 1986 and 2006 was undertaken. Left
ventricular assist devices were used pretransplant in 23 of these 317 patients, and
294 patients did not require left ventricular assist device support. Patients with
a left ventricular assist device were supported with a Heartmate VE or Heartmate
XVE (Thoratec Corp, Pleasanton, Calif). Kaplan–Meier survival estimates were com-
pared between the left ventricular assist device group and the non-left ventricular as-
sist device group using the log-rank test. In addition, occurrence of death was
analyzed between the 2 groups with a chi-square analysis. The results are expressed
as 1-year survival with 95% confidence intervals in parentheses.
Results: The 1-year survival for all 317 patients was 0.86 (0.82–0.90). The patient sur-
vival for the group without a left ventricular assist device before cardiac transplant
was 0.87 (0.83–0.90), and the survival for the group with a left ventricular assist de-
vice as bridge to transplantation was 0.83 (0.67–0.98; P 5 .77). For the deaths that
occurred in all 317 patients, 19% of the patients without left ventricular assist devices
died within 30 days of transplant, whereas 80% of the patients with left ventricular
assist devices died within 30 days of transplant (P , .01).
Conclusion:When used as a bridge to transplantation, left ventricular assist devices do
not compromise 1-year survival after cardiac transplantation. Of the patients who die
after transplantation, patients bridged with left ventricular assist devices are at higher
risk for death within 30 days of transplant. These data suggest that left ventricular
assist devices as a bridge to transplantation should be considered for appropriately
selected patients awaiting cardiac transplantation.
C
ardiac transplantation is the accepted therapy for the treatment of end-stage
heart failure. Indeed, because of the widespread application and success of
cardiac transplantation, the need for more hearts than could be supplied by
suitable donors rapidly developed. With potential heart transplant recipients dying
on waiting lists because of a supply–demand imbalance for organs, the incentive to
develop a reliable mechanical circulatory support device ensued. Portner and
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LVAD 5 left ventricular assist device
colleagues1 reported the first successful cardiac transplant af-
ter bridging with a left ventricular assist device (LVAD) at
Stanford University. This remarkable clinical milestone
opened a new option for patients with decompensated heart
failure who might otherwise die while awaiting transplanta-
tion. The use of an LVAD as a bridge to transplantation is
now accepted for patients listed for transplant whose condi-
tions deteriorate before a donor heart becomes available.2,3
In the past, the use of a pretransplant LVAD was a risk factor
for death after cardiac transplantation.4 However, 2 recent re-
ports5,6 from separate transplant centers indicate that patients
can be successfully bridged to transplant with an LVAD with
equivalent outcomes to patients undergoing transplantation
in these centers without LVAD placement. These reports
now question whether pretransplantation LVAD use adversely
affects short- and long-term survival after cardiac transplanta-
tion. We evaluated our center’s 1-year post-cardiac transplant
survival in patients undergoing transplantation with the sup-
port of the Heartmate VE or XVE LVAD (Thoratec Corp,
Pleasanton, Calif) and in patients undergoing transplantation
without LVAD support to determine whether LVAD implanta-
tion adversely affected 1-year survival.
Materials and Methods
We retrospectively reviewed 317 consecutive patients undergoing
cardiac transplantation at the University of Colorado Health Sci-
ences Center from 1986 to 2006. Pretransplant LVADs were placed
in 23 of these 317 patients (LVAD group). The criteria for place-
ment of an LVAD included patients with end-stage heart failure
whose conditions deteriorated clinically while listed for heart trans-
plantation despite inotropic or intra-aortic balloon counterpulsation
support. At the University of Colorado Health Sciences Center, we
initiated the bridge-to-transplant program with the Heartmate VE
LVAD in October of 2000. The patients included in the present anal-
ysis represented all patients who underwent planned LVAD place-
ment after a joint decision by the attending cardiothoracic surgeon
and heart failure cardiologist. We excluded any patients with acute
decompensation or a fulminant presentation who required extracor-
poreal membrane oxygenation or placement of a Thoratec ventricu-
lar assist device or Abiomed system (Abiomed, Danvers, Mass) as
a bridge to either transplant or another device. In total, 28 patients
underwent LVAD placement for bridge to transplant. The Heart-
mate VE LVAD was used in 10 patients, and the Heartmate XVE
LVAD was used in 18 patients. No pretransplant LVAD support
was used in 294 patients (NO LVAD group). This study received ap-
proval from the Colorado Multiple Institutional Review Board.
Immunosuppression posttransplant consisted of a calcineurin
inhibitor (cyclosporine or tacrolimus), an antiproliferative agent
(mycophenolate mofetil or azathioprine), and corticosteroids. The
routine use of induction therapy with antithymocyte globulin orThe Journal of ThoOKT3 was not used; however, the use of lymphocytic agents was
used only if renal function was compromised after transplant.
Demographic variables were compared between the 2 groups
with the Student t test. Kaplan–Meier survival estimates were com-
pared between the LVAD and NO LVAD groups with the log-rank
test. The occurrence of death was also analyzed between groups
with a chi-square analysis. The primary end point for this study
was 1-year survival after transplantation.
Results
Pretransplant demographic and other clinical variables
showed differences between the 2 groups (Table 1). In general,
the patients in the LVAD group were younger and had greater
body mass index, and the total graft ischemic time was longer
in the LVAD group compared with the NO LVAD group. The
percentage of patients with diabetes was similar between 2
groups, whereas the use of inotropes at the time of transplant
was lower in the LVAD group. Although serum creatinine at
the time of transplant was lower in the LVAD group, this value
did not reach significance. Two patients with an LVAD who
died early (,30 days) underwent transplantation with a docu-
mented device infection; none of the other 21 patients had clin-
ical evidence of infection. Of the 28 patients with LVADs
placed as bridge to transplant, 5 died after LVAD explantation
while awaiting a donor heart (1 anoxic brain injury, 3 multiple
systems organ failure, and 1 sudden cardiac death at home on
day 71 of support). Thus, 23 patients comprised the LVAD
group who underwent transplantation.
The 1-year survival was 82% for the LVAD group
(Figure 1) and 87% for the NO LVAD group (Figure 2)
TABLE 1. Baseline demographics and clinical
characteristics
LVAD (n 5 23) NO LVAD (n 5 294) P value
Age (y) 45 6 12 52 6 12 ,0.05
Cardiac diagnosis (%) ,0.05
Ischemic 55 32
Dilated 36 47
Other 9 21
BMI 29 6 5 25 6 5 ,0.05
Gender (M/F) 77%/23% 82%/18% NS
Diabetes mellitus (%) 18 18 NS
Duration mechanical
support (d)
165 6 122 - -
Inotrope use (at time of
transplant) (%)
5 24 ,0.05
LVEF (at listing) (%) 17 6 5 22 6 6 ,0.05
Creatinine mg/dL (at
transplant)
1.2 6 0.5 1.4 6 0.5 0.2
Ischemic time (min) 245 6 60 175 6 61 ,0.05
LVAD, Left ventricular assist device; BMI, body mass index; LVEF, left
ventricular ejection fraction; NS, not significant. Values are presented as
mean 6 standard deviation.racic and Cardiovascular Surgery c Volume 136, Number 3 775
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of 317 patients after transplantation, 19% of the NO LVAD
group died within 30 days of transplant, and 80% of the
LVAD group died within 30 days of transplant (P , .01).
One-year survival after transplantation in the entire group
of 317 patients is 87%.
With regard to specific causes of death, there were 4
deaths within 30 days in the LVAD group. Two patients
died of early graft failure (right ventricular dysfunction in 1
patient and global graft dysfunction in 1 patient). One patient
died of a cardiovascular accident/brain injury, and 1 patient
died of multiple organ failure at 3 weeks (predominantly
liver/infectious causes). The remaining death in the LVAD
group occurred at 2.5 years posttransplant. In contradistinc-
tion, the NO LVAD group sustained 23 deaths within the first
30 days (7% early mortality). A total of 13 of the 23 deaths
were caused by graft failure. This group included some of
our earliest patients who underwent transplantation. Four
deaths were secondary to brain injury/cardiovascular acci-
dent, 1 death was due to a severe acute rejection, 2 deaths
had infectious-related causes, and 3 deaths were due to bleed-
ing complications. The remaining 15 deaths occurred be-
tween 30 days and 365 days posttransplant, with more than
half (9/15) related to infectious causes, 2 rejections, 1 anoxic
brain injury, 1 sudden death (presumed graft failure), and 2
related to multiple organ failure/failure to thrive.
Discussion
LVAD therapy has been accepted as a viable strategy to
bridge patients safely to transplantation. The impact of pre-
transplantation LVAD on posttransplantation outcomes,
however, is variable. Until recently, results from the Interna-
tional Society for Heart & Lung Transplantation database
suggested that the presence of an LVAD at the time of trans-
plantation conferred an adverse risk for 1-year mortality. The
perception among most transplantation centers is that explan-
tation of an LVAD confers a more technically challenging
Figure 1. Kaplan–Meier survival analysis for 294 patients in the
NO LVAD group after cardiac transplant is 0.87 with 95% confi-
dence interval of 0.83 to 0.90.776 The Journal of Thoracic and Cardiovascular Surgery c Sepoperation and therefore might adversely affect survival. In-
deed, the ischemic time for the donor heart from the LVAD
group was significantly longer than the ischemic time in
the NO LVAD group, which likely reflected the complexity
involved in explanting the LVAD (Table 1).
In the present study, we observed excellent and compara-
ble 1-year survival after heart transplantation in both the
LVAD and NO LVAD groups. No survival decrement ex-
isted for the LVAD group at 1 year after transplantation.
An important distinction, however, remains on the timing
of death after transplantation between the 2 groups. For pa-
tients who die after transplantation, most of the LVAD group
(80% of deaths after transplant in this group) died within 30
days of transplant. In contrast, a minority of the patients with-
out an LVAD died within 30 days of transplantation. It re-
mains likely that this pattern of death after transplantation
reflects the inherent complexity and higher risk operation
that occurs with explantation of an LVAD at the time of trans-
plantation. Also, 2 of the 4 patients in the LVAD group who
died early after transplantation had clinical evidence of de-
vice infection at the time of transplantation. One of these 2
patients underwent transplantation very early after his
LVAD implantation, and our program now strongly avoids
early (,30 days since LVAD placement) device explantation
and transplantation. Our preference is to defer transplant in
our LVAD group until patients are ambulatory and nutrition-
ally replete, and have demonstrated end-organ recovery from
decompensated heart failure and subsequent physiologic
stress after LVAD implantation. The other causes of death
in the remaining 2 patients were graft dysfunction and severe
neurologic injury. Although the NO LVAD group sustained
more than half of their early deaths secondary to graft dys-
function, the details remain difficult to define in this retro-
spective study. Many of these deaths occurred earlier in the
transplantation group, in the first years of our program, and
may reflect differential expertise with donor management,
greater experience with recipient management, and overall
Figure 2. Kaplan–Meier survival analysis for 23 patients in the
LVAD group after cardiac transplant is 0.83 with 95% confidence
interval of 0.67 to 0.98.tember 2008
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confounding differences between the LVAD group and the
NO LVAD group that certainly exist in this retrospective
study may account for this differential early mortality.
Two other centers with extensive LVAD as bridge to
transplantation experience recently reported results similar
to the present study. Morgan and colleagues,6 at Columbia
Presbyterian, reported their experience with the Heartmate
LVAD for a 12-year period. They noted no difference in 1-
year survival after transplantation with an LVAD versus
those patients without an LVAD. They noted an incremental
improvement in patients’ survival as they transitioned from
the Heartmate IP to the Heartmate VE to the Heartmate
XVE device. It can be argued, however, that their improve-
ment in survival was a function of incremental experience
with the LVAD as a bridge to transplantation rather than at-
tributes of the device. Drakos and colleagues,5 from the Utah
Transplantation Affiliate Hospitals, reported similar 1-year
survival after transplant in patients with an LVAD (85%) ver-
sus those without an LVAD (92%). Both of these studies
were also retrospective reports.
Our study differs from these previously reported studies,
in that the Drakos study included 2 devices: the Heartmate
and the CardioWest Total Artificial Heart (SynCardia Sys-
tems Inc, Tucson, Ariz). Our study included only patients
who underwent transplantation with a Heartmate LVAD
and, most important, reflected our ‘‘learning curve’’ as we ini-
tiated our Heartmate LVAD program in 2000. We included
every patient who underwent transplantation with a Heart-
mate LVAD since we began using this device in our program.
Thus, although both the Columbia and Utah Transplantation
Affiliate Hospitals reports represent larger volume centers
with a greater cumulative experience than most programs,
the present study reports similar outcomes in a program
with modest experience and reflects our initial and most re-
cent implant successes and failures. Our outcomes in this
study reflect the increasingly observed effect of patient selec-
tion as a critical determinant of post-LVAD survival. We did
not include patients who had such an acute decompensation
that they manifested irreversible end-organ damage after
LVAD placement.
Several limitations of the present study must be consid-
ered. First, this study is retrospective. Inherent bias, such as
selection of patients for an LVAD as a bridge to transplanta-
tion, is a legitimate criticism. The use of historical controls to
compare the LVAD cohort with the non-LVAD cohort intro-
duces confounding effects of other therapies in the more re-
cent transplant recipients as an uncontrolled variable that
could improve the results in the LVAD cohort. Countering
this argument is the observation that our overall transplant
1-year survival has remained stable at 87% for several years
in our program. The small number of the LVAD group ana-
lyzed relative to the larger cohort may have resulted in a type
II statistical error, which accounted for our lack of differenceThe Journal of Thorin 1-year survival. Our report is from a single center with
modest transplant and LVAD volumes. As such, we would
still advocate that other cumulative experience, such as the
International Society for Heart & Lung Transplantation data-
base or outcomes from the INTERMACs database, might
provide a much more comprehensive composite experience
from the transplant and LVAD community. We did not com-
pare the survival of the NO LVAD group to transplantation
with the 28 patients who originally received LVADs. Be-
cause 5 patients in the LVAD group died while awaiting
transplantation, we elected to begin the analysis with the 23
patients who survived until transplant. We did not have reli-
able data to compare the survival of the NO LVAD group at
the time of listing with the LVAD group at the time of listing.
Thus, the current study must be interpreted with this caveat.
Conclusions
Our data suggest that the use of an LVAD as a bridge to trans-
plantation does not compromise 1-year survival after cardiac
transplantation. In patients who died after transplantation,
there is a differential timing of death after transplantation in
patients with an LVAD. The LVAD group sustained death
very early after transplant (within 30 days) compared with
the NO LVAD group. The challenges of transplants with
an LVAD as a bridge to transplantation remain, and we
would still maintain that the explantation of an LVAD fol-
lowed by transplantation is a technically challenging opera-
tion. However, our data suggest that appropriately selected
patients for an LVAD as a bridge to transplantation fare as
well as their non-LVAD counterparts. These data continue
to support the judicious use of an LVAD as a bridge to trans-
plantation and demonstrate that even in centers with a modest
experience, good outcomes for transplantation after LVAD
can be achieved.
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